Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Environmental Impact Acquisition Corp. (ENVIU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.41-0.02 (-0.19%)
At close: 03:17PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.43
Open10.43
Bid10.16 x 1800
Ask10.75 x 4000
Day's Range10.41 - 10.45
52 Week Range9.77 - 11.84
Volume4,261
Avg. Volume2,435
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals

    RTP biotech primed for expansion on heels of $1.2B SPAC deal

    A biotechnology firm that researches and manufactures ribonucleic acid, or RNA, for use in human and plant health is expanding its footprint in Research Triangle Park ahead of the expected approval of its first product and its entrance onto the public markets. Massachusetts-based GreenLight Biosciences started research and development in RTP for the plant health side of its business near the beginning of the Covid-19 pandemic. About two years later, the company is expanding into a facility that includes 40,000 square feet of lab and office space and 15,000 square feet of greenhouse space.

  • Benzinga

    RNA Tech Vaccine Developer GreenLight Biosciences Riding To NASDAQ Debut Via $1.5B SPAC Deal

    GreenLight Biosciences Inc is combining with a special-purpose acquisition company to go public in a deal that values the RNA-technology firm at about $1.5 billion. GreenLight is merging with Environmental Impact Acquisition Corp (NASDAQ: ENVI), which is backed by investment bank Canaccord Genuity Group Inc. GreenLight's ribonucleic acid (RNA) platform has developed candidates for COVID-19, influenza, and earlier-stage programs in sickle cell disease. It is simultaneously working on RNA-based su

  • Simply Wall St.

    What You Need To Know About Environmental Impact Acquisition Corp.'s (NASDAQ:ENVI) Investor Composition

    Every investor in Environmental Impact Acquisition Corp. ( NASDAQ:ENVI ) should be aware of the most powerful...

Advertisement
Advertisement